UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 21, 2015
NEOTHETICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware |
|
001-36754 |
|
20-8527075 |
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification Number) |
9171 Towne Centre Drive, Suite 270, San Diego, CA 92122
(Address of principal executive offices, with zip code)
(858) 750-1008
(Registrant’s telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 21, 2015, Neothetics, Inc. (the “Company”) agreed to terms of separation of employment with Lincoln Krochmal, the Company’s Chief Medical Officer, effective January 21, 2016 (the “Separation Date”). In connection with his departure, and subject to entry into an effective release and waiver of claims from Dr. Krochmal, the Company has agreed to provide Dr. Krochmal (a) a cash payment equal to six months of base salary currently in effect, payable in accordance with the Company’s regular payroll cycle beginning on the first regular payday occurring 60 days following the Separation Date, and (b) payment of the premiums required to continue Dr. Krochmal’s group health coverage for a period of six months following the Separation Date.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NEOTHETICS, INC.
|
Date: December 23, 2015 |
By: /s/ George W. Mahaffey |
George W. Mahaffey
President and Chief Executive Officer